<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Anapaula Valarezo on Medium]]></title>
        <description><![CDATA[Stories by Anapaula Valarezo on Medium]]></description>
        <link>https://medium.com/@anapaula.valarezo2009?source=rss-ef906be40b7e------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*GCe1a1djtx0_GwqT</url>
            <title>Stories by Anapaula Valarezo on Medium</title>
            <link>https://medium.com/@anapaula.valarezo2009?source=rss-ef906be40b7e------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 17:19:01 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@anapaula.valarezo2009/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Next-Generation iPSC Organoids: Integrating Microfluidics and Genetic Engineering Toward…]]></title>
            <link>https://medium.com/@anapaula.valarezo2009/next-generation-ipsc-organoids-integrating-microfluidics-and-genetic-engineering-toward-c82b4fad7c3b?source=rss-ef906be40b7e------2</link>
            <guid isPermaLink="false">https://medium.com/p/c82b4fad7c3b</guid>
            <category><![CDATA[synthetic-biology]]></category>
            <category><![CDATA[bioengineering]]></category>
            <category><![CDATA[tissue-engineering]]></category>
            <dc:creator><![CDATA[Anapaula Valarezo]]></dc:creator>
            <pubDate>Sun, 15 Nov 2026 15:12:08 GMT</pubDate>
            <atom:updated>2026-11-15T15:12:08.920Z</atom:updated>
            <content:encoded><![CDATA[<h3><em>Next-Generation iPSC Organoids: Integrating Microfluidics and Genetic Engineering Toward Transplantable Tissue Engineering</em></h3><h4>What If Your Own Cells Could Become the Foundation of a New Organ?</h4><p>Imagine a future in which the starting material for repairing a damaged organ does not come from a donor, but from the patient themselves. A small population of their own cells could potentially be reprogrammed, directed toward specialized cell types, and organized into three-dimensional structures designed to reproduce selected functions of human tissues (World Health Organization, 2024).</p><p>This possibility is no longer purely theoretical. Advances in stem-cell biology have made it possible to reset the developmental identity of differentiated cells, opening new possibilities for regenerative medicine. Yet, an important distinction remains: generating the cells needed to build a tissue is not the same as engineering a functional, transplantable structure.</p><p>Organ transplantation remains a life-saving treatment for severe organ failure, but the availability of suitable donor organs remains far below global demand. This gap has driven interest in regenerative medicine and tissue engineering, which aim to restore or replace damaged biological structures by combining living cells with controlled biological and physical environments.</p><p>At the center of this research is a deceptively simple question: if a patient’s own cells can be given a new identity, could they eventually become the building blocks of replacement tissue?</p><p>The answer begins with induced pluripotent stem cells (iPSCs) — but turning these cells into functional tissue requires solving a much harder problem: how to make bullions of cells survive, organize, mature, and communicate within a three-dimensional structure. This is where organoids, microfluidic systems, vascularization, and genetic engineering begin to converge.</p><h4>1. Rewriting Cellular Identity</h4><p>A major breakthrough in this field came in 2006 when Kazutoshi Takahashi and Shinya Yamanaka demonstrated that differentiated mouse fibroblasts could be reprogrammed into induced pluripotent stem cells (iPSCs). By introducing four transcription factors — Oct3/4, Sox2, Klf4, and c-Myc — the researchers were able to reset the cells into a state resembling embryonic stem cells (Takahashi &amp; Yamanaka, 2006).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*9MaEBSw8vnsQ49wF" /><figcaption><em>Figure 1. Schematic representation of cellular reprogramming: differentiated somatic cells are exposed to the Yamanaka factors and converted into induced pluripotent stem cells.</em></figcaption></figure><p>The idea behind this process is surprisingly powerful. A differentiated cell is specialized for a particular function, but its identity is not permanently fixed. Through cellular reprogramming, changes in gene expression and epigenetic state can push the cell back toward a pluripotent state. In other words, scientists are not simply making the cell “younger”; they are altering the regulatory program that determines which genes the cell uses and, consequently, what it can become.</p><p>The next question is what these reprogrammed cells can actually do.</p><p>Pluripotency refers to the ability of a cell to differentiate into cell types derived from all three embryonic germ layers: ectoderm, mesoderm, and endoderm. These layers give rise to many tissues and cell types throughout the body. Under appropriate differentiation conditions, iPSCs can serve as a starting population for generating specialized cells such as neurons, cardiomyocytes, hepatocytes, or other lineage-specific cells.</p><p>The significance of this became even greater in 2007, when Takahashi and colleagues successfully generated iPSCs from adult human fibroblasts using the same four factors (Takahashi et al., 2007). The transition from mouse to human cells transformed iPSCs technology from an experimental proof of concept into a platform with much broader potential for studying human development, disease, and regenerative medicine.</p><p>But there is an important limitation.</p><p><strong>Having the right cells does not mean having the right tissue.</strong></p><p>A functional organ depends not only on which cells are present, but on how those cells are spatially organized, how they communicate, how they receive oxygen and nutrients, and how they respond to mechanical and biochemical signals. This is why simply producing large numbers of iPSCs is not enough.</p><p>Researchers therefore began looking for ways to make these cells organize themselves into three-dimensional structures that closely resemble native tissue.</p><p>That brings us to the next step: <strong>organoids.</strong></p><h4>2. The 200-Micrometer Problem</h4><p>Once iPSCs have been differentiated into specialized cells, the next challenge is to organize them into a structure that behaves more like actual tissue. This is where organoids became useful. Organoids are three-dimensional, self-organizing cellular models that reproduce selected structural and functional characteristics of organs. Their architecture allows researchers to study cell — cell interactions and tissue organization in a way that conventional two-dimensional cultures cannot fully reproduce.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*xLbAntCSTbPLxJV8" /><figcaption><em>Figure 2. Representative microscopy image of a stem-cell-derived organoid, illustrating its three-dimensional organization.</em></figcaption></figure><p>But increasing dimensionality introduces a new problem: <strong>transport.</strong></p><p>In a conventional organoid culture, oxygen and nutrients are supplied by the surrounding culture medium and must move through the tissue largely by diffusion. Diffusion is effective over short distances, but it becomes increasingly inefficient as the distance between a cell and its oxygen source grows. In mammalian tissue, oxygen and nutrient difusion is commonly estimated to be limited to roughly 100–200 μm<strong>, </strong>although the exact distance depends on factors such as cell density, oxygen consumption, tissue geometry, and the surrounding environment (Nwokoye &amp; Abilez, 2024).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/926/0*JFFcKG3F30R9iuMV" /><figcaption>Figure3. <em>Schematic representation of oxygen diffusion in a three-dimensional organoid. As diffusion distance increases, oxygen availability decreases toward the interior, potentially generating hypoxic and necrotic regions.</em></figcaption></figure><p>This creates a spatial gradient inside the organoid. Cells near the surface remain relatively close to the source of oxygen and nutrients, while cells deeper inside must rely on molecules traveling farther through the tissue. As organoids become larger and more metabocally active, the balance between oxygen delivery and cellular consumption becomes increasingly difficult to maintain. The resulting hypoxic conditions can impair cell survival and maturation and, in sufficiently large constructs, contribute to the formation of a necrotic core.</p><p>The problem can therefore be understood as a simple physical relationship:</p><p>more cells — greater oxygen demand — longer diffusion distnaces — greater risk of hypoxia.</p><p>This is why simply growing a larger organoid does not automatically bring reasearchers closer to building a functional organ. A larger structure requires not only more cells, but also a more effective way of delivering resources to those cells.</p><p>And this is where tissue engineering begins to borrow a solution from the human body itself.</p><p>The circulatory system does not rely on oxygen simply diffusing across an entire organ. Instead, an enormous network of blood vessels continuously transports oxygen, nutrients, hormones, and other molecules close to individual cells while carrying metabolic waste away.</p><p>So if engineered tissues are going to become larger and more complex, perhaps they need their own version of a circulatory system.</p><p><strong>The question is no longer simply how to grow an organoid. It is how to give one a lifeline.</strong></p><h4>3. Engineering a Biological Lifeline</h4><p>The diffusion problem reveals a fundamental limitation of conventional organoid culture: cells cannot simply be placed together and expected to sustain themselves as the tissue grows. Native organs solve this problem through vascular networks that continuously deliver oxygen and nutrients while removing metabolic waste. Tissue engineers therefore face a more ambitious challenge — recreating at least some of the transport and signaling functions normally provided by the circulatory system.</p><p>One promising approach is microfluidics. Microfluidic platforms use small, precisely engineered channels to control the movement of fluids around and through biological tissues. When organoids are incorporated into these systems, researchers can regulate factors such as flow rate, nutrient delivery, oxygen availability, and mechanical forces within a much more controlled environment than conventional static culture. Recent work on vascularized organoid-on-chip systems identifies controlled perfusion as a key strategy for overcoming diffusion limitations and improving the physiological relevance of organoids (Menzani et al., 2026).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*Dsj7OJgthsBfTnDQ" /><figcaption><strong>Figure 4.</strong> <em>Conceptual representation of a vascularized organoid-on-chip system. Microfluidic channels provide controlled fluid flow, while endothelial cells can form vascular-like structures that support transport within the engineered tissue.</em></figcaption></figure><p>A channel carrying culture medium around an organoid is fundamentally different from a vascular network inside the tissue. To move toward physiological tissue organization, researchers are therefore exploring the incorporation of endothelial cells, the cells that line blood vessels. These cells can organize into vessel-like structures and, under appropriate biochemical and mechanical conditions, participate in processes such as angiogenesis — the formation of new blood vessels from existing vascular structures (Menzani et al., 2026).</p><p>This distinction is important because the goal is not simply to make fluid move. It is to create a biological interface capable of interacting with the surrounding tissue.</p><h4>Flow Is More Than Transportation</h4><p>There is another reason microfluidics is particularly interesting: fluid flow can become a biological signal.</p><p>As fluid moves through a vascular structure, it generates forces against the endothelial cells lining its walls. One of these forces, shear stress, can influence endothelial behavior, including changes in gene expression, cell alignment, permeability, and vascular remodeling. In other words, flow is not merely delivering nutrients — it can provide mechanical information that cells respond to (Menzani et al., 2026).</p><p>This creates a much more sophisticated engineering strategy:</p><p>microfluidics → controlled flow → mechanical signals → endothelial response → vascular organization.</p><p>Instead of simply keeping the organoid alive, researchers can begin to manipulate the physical environment in which the tissue develops.</p><p>A notable example comes from work on kidney organoids cultured within microfluidic systems. Homan et al. demonstrated that kidney organoids could be incorporated into microfluidic chips containing vascular structures, allowing researchers to investigate how controlled fluid flow and vascular organization could influence tissue development (Homan et al., 2019). The study provided an important proof of concept for combining organoid biology with engineered microenvironments rather than treating the organoid as an isolated structure.</p><p>However, this is where the challenge becomes even more interesting.</p><p><strong>A vascular network is not simply a collection of endothelial cells.</strong></p><p>In native tissues, blood vessels interact with multiple cell types, extracellular matrix components, biochemical signals, and mechanical forces. The vascular system is also highly specialized: the vessels supplying the brain do not have exactly the same properties as those supplying the kidney or liver. Recent organoid-on-chip research therefore emphasizes the importance of combining endothelial cells with supporting populations such as pericytes, fibroblasts, or other stromal cells to produce more stable and physiologically relevant vascular structures (Menzani et al., 2026).</p><p>This means that successful vascularization requires more than building a pipe.</p><p>It requires engineering an ecosystem.</p><p>And even that may not be enough.</p><p>If we can control the physical environment around an organoid, the next question becomes whether we can also control the biological instructions inside its cells.</p><p>That is where genetic engineering enters the picture.</p><h3>4. Programming Growth, Engineering Safety</h3><p>Microfluidics can help solve the <strong>physical</strong> problem of delivering oxygen and nutrients, but tissue development is not controlled by physics alone. Cells also respond to molecular signals that tell them when to grow, migrate, differentiate, and organize. If vascularization is going to be engineered rather than simply observed, researchers need ways to influence those biological instructions as well.</p><p>This is where <strong>genetic engineering</strong> becomes particularly interesting.</p><p>One approach is <strong>CRISPR activation, or CRISPRa</strong>. Unlike conventional CRISPR-Cas9 genome editing, which can be used to cut DNA, CRISPRa uses a catalytically inactive Cas9 protein, often called <strong>dCas9</strong>, coupled to transcriptional activator domains. Guided by an RNA molecule, the system can be positioned near a specific gene and increase its expression without cutting the DNA sequence itself. Gilbert et al. (2013), for example, demonstrated that dCas9-based transcriptional activators could be programmed to regulate endogenous gene expression in eukaryotic cells, establishing an important foundation for CRISPR activation technologies.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/730/0*yZc_96B6biWIycu-" /><figcaption><strong>Figure 5.</strong> <em>CRISPR activation (CRISPRa) uses a catalytically inactive Cas9-based system to increase transcription of a selected endogenous gene.</em></figcaption></figure><p>In the context of engineered tissues, this creates an intriguing possibility. Instead of introducing an entirely artificial growth program, researchers could potentially <strong>activate genes already present in the cell’s genome</strong> to influence processes relevant to vascular development. For example, increasing the activity of pro-angiogenic pathways could help create a cellular environment more favorable to vascular network formation.</p><p>However, this is where we need to be careful with the word <strong>“could.”</strong> CRISPRa does not automatically produce a functional vascular network, and activating an angiogenic gene is not equivalent to successfully vascularizing an organoid. The outcome depends on which gene is targeted, which cells receive the signal, when it is activated, and how that signal interacts with the surrounding tissue. In fact, CRISPRa systems themselves can behave differently as iPSCs differentiate; one study found that a CRISPRa system effective in pluripotent cells could become silenced after differentiation into cardiomyocytes and endothelial cells (Karbassi et al., 2024).</p><p>This illustrates an important principle of synthetic biology:</p><p><strong>more control does not necessarily mean perfect control.</strong></p><p>The more biological variables researchers attempt to manipulate, the more important it becomes to build mechanisms that can respond when something goes wrong.</p><h3>Engineering an Emergency Brake</h3><p>For iPSC-based tissue engineering, safety is particularly important because pluripotent cells have the capacity for extensive self-renewal, and residual undifferentiated cells can contribute to unwanted growth after transplantation. This has motivated researchers to develop <strong>genetic safety switches</strong> that allow engineered cells to be eliminated if necessary.</p><p>One example is <strong>inducible caspase-9 (iCasp9)</strong>. The system introduces a modified form of the human caspase-9 protein that remains inactive until exposed to a specific chemical dimerizer. Activation brings the engineered caspase molecules together, triggering the cell’s programmed cell-death pathway. In human iPSCs, researchers have demonstrated that iCasp9 can be introduced while preserving pluripotency and subsequently activated to eliminate the engineered cells (Yagyu et al., 2015).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/512/0*pNlk5_4ZF2g5q5bL" /><figcaption><strong>Figure 6.</strong> <em>Conceptual mechanism of an inducible caspase-9 safety switch. A chemical inducer activates the engineered caspase pathway, allowing the elimination of cells carrying the safety system.</em></figcaption></figure><p>This does not make an engineered tissue automatically safe. In fact, later research has shown that even iCasp9 systems can have limitations, including the possibility of rare cells escaping elimination through mechanisms such as genetic loss or transgene silencing. These findings highlight why safety systems must themselves be rigorously tested rather than treated as a guarantee of biological control.</p><p>And this brings the different technologies together.</p><p><strong>Microfluidics controls the environment.</strong></p><p><strong>Vascularization addresses transport.</strong></p><p><strong>Genetic engineering can influence cellular behavior.</strong></p><p><strong>Safety switches provide an additional layer of control.</strong></p><p>Together, these approaches begin to transform the organoid from a relatively passive biological model into something closer to an <strong>engineered living system</strong>.</p><p>But there is still a major gap between engineering an organoid that survives in a laboratory and creating tissue that could function safely inside a human body.</p><p>That is the final challenge: <strong>can an engineered organoid become something more than a model — and eventually become functional tissue?</strong></p><h3>5. Beyond the Organoid: From Model to Functional Tissue</h3><p>At this point, the pieces begin to fit together. iPSCs provide a potentially patient-specific starting population. Organoids give those cells a three-dimensional architecture. Microfluidic systems can improve transport and expose developing tissues to controlled physical signals. Genetic engineering may provide additional control over cellular behavior and safety.</p><p>But there is still a fundamental difference between <strong>engineering an organoid that survives in the laboratory and engineering tissue that can function inside a human body</strong>.</p><p>Current organoids reproduce selected features of organs, but they remain simplified models. Many are limited by incomplete maturation, variability between batches, insufficient vascularization, and an inability to fully reproduce the complex cellular and extracellular environment of adult tissues (Andersson-Rolf &amp; Clevers, 2026).</p><p>This distinction becomes especially important when considering transplantation. A tissue intended for implantation cannot simply remain biologically isolated. It must establish a stable connection with the recipient, receive adequate blood supply, integrate with surrounding tissue, and maintain its function over time.For example, Koning et al. (2022) demonstrated that human iPSC-derived kidney organoids transplanted into chicken embryos could develop perfused capillary networks involving both organoid-derived and host-derived endothelial cells. Although this represents an important advance in vascularization and maturation, it does not demonstrate the clinical transplantation of a functional human kidney.</p><p>There is also the problem of <strong>maturation</strong>.</p><p>Many iPSC-derived organoids resemble aspects of developing or fetal tissue rather than fully mature adult organs. Their cells may possess the correct identity while lacking some of the structural organization, physiological activity, or specialized functions found in adult tissue (Hofer &amp; Lutolf, 2021).</p><p>This creates another engineering question:</p><p><strong>What if the problem is no longer making the tissue grow, but teaching it how to become mature?</strong></p><p>Microfluidics could contribute by providing controlled mechanical and biochemical environments. Genetic engineering could provide more precise control over cellular programs. Vascularization could improve oxygen delivery and create communication between the tissue and its surrounding environment. But none of these technologies solves every problem independently.</p><p>The ultimate goal, therefore, is not to build a perfect organoid using one technology.</p><p>It is to <strong>integrate multiple layers of control into one living system</strong>.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*V9OSgvjd8tUIhGeZ" /><figcaption><strong>Figure 7.</strong> <em>Conceptual framework for integrating iPSCs, organoid formation, microfluidic perfusion, vascularization, and genetic engineering toward functional engineered tissue.</em></figcaption></figure><p>The future of this field will therefore depend as much on <strong>integration</strong> as on individual breakthroughs. A successful engineered tissue would need to coordinate cellular identity, three-dimensional architecture, vascular transport, mechanical signaling, maturation, and safety rather than treating each problem separately.</p><p>And there is an important reason to remain cautious. Patient-derived iPSCs may offer biological advantages, but using a person’s own cells does <strong>not automatically eliminate immune or genetic risks</strong>. Clinical translation still faces challenges involving genomic and epigenetic abnormalities, tumor formation, immune responses, reproducibility, large-scale manufacturing, and long-term tissue integration (Dhaiban et al., 2025).</p><p>So the most realistic future is not a laboratory-grown replacement organ appearing overnight.</p><p>It is a gradual progression:</p><p>reprogram the cell → guide its identity → organize the tissue → provide transport → regulate its development → test its safety → establish functional integration.</p><p>Each step solves a different biological bottleneck.</p><p>And that is what makes the convergence of <strong>iPSC biology, organoids, microfluidics, vascular engineering, and synthetic biology</strong> so significant. None of these technologies alone is enough to recreate a human organ. Together, however, they offer a framework for moving tissue engineering from simply <strong>culturing cells</strong> toward deliberately <strong>engineering living systems</strong>.</p><p>The question is no longer whether scientists can make cells change their identity.</p><p>They can.</p><p>The more difficult question is whether we can make those cells <strong>organize, mature, communicate, and function as tissue</strong> — and eventually do so safely enough to become part of a patient.</p><p>That is the challenge that the next generation of organoid engineering will have to solve.</p><h3>References</h3><p>Andersson-Rolf, A., &amp; Clevers, H. (2026). New developments and applications of human organoids. <em>Nature Reviews Molecular Cell Biology, 27</em>, 543–558. <a href="https://doi.org/10.1038/s41580-026-00974-0">https://doi.org/10.1038/s41580-026-00974-0</a></p><p>Dhaiban, S., Chandran, S., Noshi, M., &amp; Sajini, A. A. (2025). Clinical translation of human iPSC technologies: Advances, safety concerns, and future directions. <em>Frontiers in Cell and Developmental Biology, 13</em>, Article 1627149. <a href="https://doi.org/10.3389/fcell.2025.1627149">https://doi.org/10.3389/fcell.2025.1627149</a></p><p>Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., Lim, W. A., Weissman, J. S., &amp; Qi, L. S. (2013). CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. <em>Cell, 154</em>(2), 442–451. <a href="https://doi.org/10.1016/j.cell.2013.06.044">https://doi.org/10.1016/j.cell.2013.06.044</a></p><p>Hofer, M., &amp; Lutolf, M. P. (2021). Engineering organoids. <em>Nature Reviews Materials, 6</em>, 402–420. <a href="https://doi.org/10.1038/s41578-021-00279-y">https://doi.org/10.1038/s41578-021-00279-y</a></p><p>Homan, K. A., Gupta, N., Kroll, K. T., Kolesky, D. B., Skylar-Scott, M., Miyoshi, T., Mau, D., Valerius, M. T., Ferrante, T., Bonventre, J. V., Lewis, J. A., &amp; Morizane, R. (2019). Flow-enhanced vascularization and maturation of kidney organoids in vitro. <em>Nature Methods, 16</em>, 255–262. <a href="https://doi.org/10.1038/s41592-019-0325-y">https://doi.org/10.1038/s41592-019-0325-y</a></p><p>Karbassi, E., Padgett, R., Bertero, A., Reinecke, H., Klaiman, J. M., Yang, X., Hauschka, S. D., &amp; Murry, C. E. (2024). Targeted CRISPR activation is functional in engineered human pluripotent stem cells but undergoes silencing after differentiation into cardiomyocytes and endothelium. <em>Cellular and Molecular Life Sciences, 81</em>, Article 95. <a href="https://doi.org/10.1007/s00018-023-05101-2">https://doi.org/10.1007/s00018-023-05101-2</a></p><p>Koning, M., Dumas, S. J., Avramut, M. C., Koning, R. I., Meta, E., Lievers, E., Wiersma, L. E., Borri, M., Liang, X., Xie, L., Liu, P., Chen, F., Lin, L., Luo, Y., Mulder, J., Spijker, H. S., Jaffredo, T., van den Berg, B. M., Carmeliet, P., … Rabelink, T. J. (2022). Vasculogenesis in kidney organoids upon transplantation. <em>npj Regenerative Medicine, 7</em>, Article 40. <a href="https://doi.org/10.1038/s41536-022-00237-4">https://doi.org/10.1038/s41536-022-00237-4</a></p><p>Menzani, B., De Gea, P., Gidrol, X., &amp; Tubbs, E. (2026). Vascularizing organoids-on-chip for perfused and personalized models. <em>Lab on a Chip, 26</em>(6), 1798–1819. <a href="https://doi.org/10.1039/D5LC00890E">https://doi.org/10.1039/D5LC00890E</a></p><p>Nwokoye, P. N., &amp; Abilez, O. J. (2024). Bioengineering methods for vascularizing organoids. <em>Cell Reports Methods, 4</em>(6), Article 100779. <a href="https://doi.org/10.1016/j.crmeth.2024.100779">https://doi.org/10.1016/j.crmeth.2024.100779</a></p><p>Takahashi, K., &amp; Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. <em>Cell, 126</em>(4), 663–676. <a href="https://doi.org/10.1016/j.cell.2006.07.024">https://doi.org/10.1016/j.cell.2006.07.024</a></p><p>Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., &amp; Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. <em>Cell, 131</em>(5), 861–872. <a href="https://doi.org/10.1016/j.cell.2007.11.019">https://doi.org/10.1016/j.cell.2007.11.019</a></p><p>World Health Organization. (2024, May 30). <em>Seventy-seventh World Health Assembly — Daily update: 30 May 2024</em>. <a href="https://www.who.int/news/item/30-05-2024-seventy-seventh-world-health-assembly---daily-update--30-may-2024">https://www.who.int/news/item/30-05-2024-seventy-seventh-world-health-assembly---daily-update--30-may-2024</a></p><p>Yagyu, S., Hoyos, V., Del Bufalo, F., &amp; Brenner, M. K. (2015). An inducible caspase-9 suicide gene to improve the safety of therapy using human induced pluripotent stem cells. <em>Molecular Therapy, 23</em>(9), 1475–1485. <a href="https://doi.org/10.1038/mt.2015.100">https://doi.org/10.1038/mt.2015.100</a></p><p>Wunderlich, S., Haase, A., Merkert, S., Jahn, K., Deest, M., Frieling, H., Glage, S., Korte, W., Martens, A., Kirschning, A., Zeug, A., Ponimaskin, E., Göhring, G., Ackermann, M., Lachmann, N., Moritz, T., Zweigerdt, R., &amp; Martin, U. (2022). Targeted biallelic integration of an inducible Caspase 9 suicide gene in iPSCs for safer therapies. <em>Molecular Therapy — Methods &amp; Clinical Development, 26</em>, 84–94. <a href="https://doi.org/10.1016/j.omtm.2022.05.011">https://doi.org/10.1016/j.omtm.2022.05.011</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c82b4fad7c3b" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>